Drug Shortage Report for HEPARIN SODIUM INJECTION, USP

Last updated on 2022-01-19 History
Report ID 148577
Drug Identification Number 02264315
Brand name HEPARIN SODIUM INJECTION, USP
Common or Proper name Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HEPARIN SODIUM
Strength(s) 1000UNIT
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS
Packaging size 1 mL
ATC code B01AB
ATC description ANTITHROMBOTIC AGENTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-11-30
Actual start date 2021-11-30
Estimated end date 2022-01-10
Actual end date 2022-01-18
Shortage status Resolved
Updated date 2022-01-19
Company comments Fresenius Kabi Canada regrets to advise that due to further production delays we will be extending the backorder on our Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 1 mL until January 10, 2022. Effective December 10, 2021, our Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 10 mL format will be available for substitution.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v11 2022-01-19 English Compare
v10 2022-01-17 French Compare
v9 2022-01-17 English Compare
v8 2021-12-03 French Compare
v7 2021-12-03 English Compare
v6 2021-12-01 French Compare
v5 2021-12-01 English Compare
v4 2021-12-01 French Compare
v3 2021-11-01 English Compare
v2 2021-11-01 French Compare
v1 2021-11-01 English Compare

Showing 1 to 11 of 11